Literature DB >> 6354297

Alterations in the components of ribonucleotide reductase in hydroxyurea-resistant hamster cells.

J A Wright, J G Cory.   

Abstract

Two components of mammalian ribonucleotide reductase have been separated by blue dextran-Sepharose chromatography from a hydroxyurea-resistant cell line, NCR-30A2, and its parental wild type. Analysis of reductase activity in these cells and the enzyme components reveals that there are three alterations involving ribonucleotide reductase activity in NCR-30A2 cells. There is an elevation in the effector-binding (EB) component, an elevation in the non-heme-iron-containing (NHI) component, and an alteration in the NHI component that renders the enzyme less sensitive to inhibition by hydroxyurea. These findings easily account for the resistance of NCR-30A2 cells to the antitumor agent hydroxyurea, and to other drugs with a similar mode of action.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354297     DOI: 10.1007/bf01120985

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  2 in total

1.  The in vivo toxicity of hydroxyurea depends on its direct target catalase.

Authors:  Trine Juul; Anna Malolepszy; Karen Dybkaer; Rune Kidmose; Jan Trige Rasmussen; Gregers Rom Andersen; Hans Erik Johnsen; Jan-Elo Jørgensen; Stig Uggerhøj Andersen
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.

Authors:  Steven Attia; Jill Kolesar; Michelle R Mahoney; Henry C Pitot; Daniel Laheru; James Heun; Wei Huang; Jens Eickhoff; Charles Erlichman; Kyle D Holen
Journal:  Invest New Drugs       Date:  2008-02-16       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.